Q-omics provides the consensus-scored CD81 profile across patient tissues and cancer cell-line models. CD81 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CD81 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CD81 protein abundance shows 31,290 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CD81 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD81 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD81 survival associations across molecular data types. CD81 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD81 RNA expression–survival associations across cancer types. High CD81 expression shows unfavorable associations in COAD, HNSC, ACC, GBM and LUSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for CD81 RNA expression.
This table summarizes CD81 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD81. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD81 shows lower tumor expression in THCA, LUAD, BLCA, UCEC and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher CD81 RNA expression in tumor versus normal tissue (log2 FC = +0.776, t-test p < 0.001).
This table shows molecular features associated with CD81 in patient tissues and cancer cell lines. In patient samples, CD81 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD81 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
